Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L22 pseudogene 24 (RPL22P24) is a processed pseudogene in the human genome, sharing sequence similarity with the gene encoding ribosomal protein L22 but not producing a functional protein product. It belongs to the group of ribosomal pseudogenes distributed throughout the genome, reflecting gene duplication and retrotransposition events. Unlike the functional RPL22 gene, which is part of the ribosome's 60S large subunit and participates in protein synthesis, RPL22P24 does not contribute to ribosome structure or function, has no recognized biological or pathological role, and is not targeted by drugs or used clinically[4][7]. In summary: RPL22P24 is a non-coding pseudogene, not a protein, receptor, enzyme, or drug target, and has no current therapeutic, biological, or clinical significance. It should not be considered or annotated as a druggable or marker target[4][7].
None (no known mechanism of action; not a target for drugs)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L22 pseudogene 24 (RPL22P24).